Today we explore the work of SynAct Pharma, an innovative biotech and healthcare startup from Lund, Sweden. Focused on the development of drugs for acute deterioration in inflammatory diseases, SynAct Pharma deploys groundbreaking approaches to address arthritis-and-psoriasis-related concerns. Could this signal the dawn of a new era in biotech healthcare?
SynAct Pharma’s work primarily centers around their drug candidate AP1189, designed specifically to treat arthritis, including psoriatic arthritis which reportedly affects nearly 30% of psoriasis patients. The company’s drive for innovation is fueled by a comprehensive understanding of the breadth and impact of these diseases. They are working to revolutionize inflammatory disease treatment, serving as a leading beacon of progress in biotech healthcare.
-
Key takeaways:
- SynAct Pharma is a leading figure in the biotech healthcare industry, specifically targeting acute deterioration in inflammatory diseases.
- The startup’s primary focus is the development and deployment of its drug candidate, AP1189.
- AP1189 is geared primarily towards the treatment of psoriatic arthritis, a prevalent condition amongst psoriasis patients.
SynAct Pharma’s approach is differentiated by the unique capabilities of AP1189. The drug candidate is believed to have the ability to not only reduce inflammation but also expedite bleeding—a crucial step in preventing joint damage following acute inflammation. The lifestyle-friendly one-tablet-per-day regimen has boosted the prospect potential of AP1189 in the eyes of both patients and healthcare professionals.
Beyond clinical convenience, SynAct’s strategic plan also distinguishes their startup. The company has already completed phase I studies and eagerly anticipates results by the second half of 2018. To maximize efficiency, they intend to concurrently prepare for a first patient study. This methodic and timely approach signals SynAct Pharma’s commitment to swift progression without compromising on safety measures and regulatory procedures.
Looking ahead, the future of SynAct Pharma and the biotech healthcare industry seems poised for transformation. Pending successful results from multiple dosing, SynAct plans to submit a clinical trial application (CTA) for active arthritis. The company also maintains a vision of collaboration, aiming to partner with one or more leading pharmaceutical companies once proof of concept has been established.
Armed with a game-changing drug, strategic approach, and far-reaching alliance plans, SynAct Pharma is set to make significant strides in the treatment of inflammatory diseases. With the healthcare needs of millions in its sight, the ambitious startup reinforces a vision of advancement in biotech healthcare that answers pressing medical demands, and even more, empowers patients with a better quality of life. Visit their website for more information or connect via Twitter, Facebook, and LinkedIn.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
